One patient each whose advanced tumors harbored high level MET amplification with wild-type PIK3CA or MET exon 14 skipping mutation with PIK3CA - p.Glu542Lys had significant responses to crizotinib ; suggesting that PIK3CA co-mutation did not affect clinical response .